Jenex Provides Update on TherOZap(TM) Working Prototype, and InterceptCS

Toronto, Ontario--(Newsfile Corp. - March 6, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex", or the "Company"). Jenex would like to report that the development of the working prototype for the patent pending TherOZap™ is scheduled for completion prior to the end of March 2017. The Company has finalized the optimal components and features for the working prototype. As previously reported Jenex expects to test the working prototype to determine its effectiveness at inactivating both the Zika virus and West Nile virus and potentially other mosquito borne diseases. Testing will be initiated by a world renowned scientific research lab upon completion of the working prototype.

Jenex would also like to report that to date it has been encouraged with the design process for TherOZap™. Due to the positive experience with the TherOZap™ design and driven by consumer requests the Company will investigate the design of a multi-use Treatment Activator for its InterceptCS product, the Company's thermal therapy device approved in Canada as a Class II medical device with a claim, "For the prevention and relief of the symptoms of herpes labialis (cold sores)."

Currently the InterceptCS Treatment Activator is good for one use and then discarded. The Company believes it has received sufficient consumer requests for multi-use Treatment Activators to warrant a redesign of the Treatment Activator product. The Company will investigate a 3, 5, and 10 use Treatment Activator housed in the same plug and play Treatment Activator housing used today. It is anticipated that the multi-use Treatment Activator will offer a discount and enhanced value to consumers on a per unit basis. Upon completion of the redesigned Treatment Activator the Company will establish an enhanced marketing campaign through social media and other channels to ramp up sales of both the InterceptCS systems and multi-use Treatment Activators. Once successfully marketed the multi-use Treatment Activator will represent a consistent recurring revenue stream for the Company.

Jenex has over 15,000 InterceptCS systems in inventory which have been written down to zero on the Company's balance sheet. The InterceptCS system retails for $49.99 online and includes two Treatment Activators. A single use Treatment Activator currently retails for $14.99. The InterceptCS product is currently sold online and at or

The Company has also granted incentive stock options to its directors and consultants to purchase up to an aggregate of 5,000,000 common shares of the Company. The options are exercisable for a period of five years at a price of $0.10 share.

All securities issued pursuant to the above distributions will be subject to statutory and Exchange imposed hold periods expiring four months and one day from the date of issuance of such securities.

Rob Fia, CEO commented:

"We are pleased to have advanced the design process further with our TherOZap™ device and excited to finalize the working prototype. We are listening to consumers and believe a redesign of our Treatment Activator used in the InterceptCS product will offer consumers increased value while providing a cost effective solution to treat cold sores."

Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997.

Jenex continues to further develop, and explore other applications, for its platform technology. If you would like to stay informed on the development of TherOZap™ or InterceptCS please visit or

About Jenex:

Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs.  Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments.  The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (TSXV: JEN.H). For more information visit: or


Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events or the Company's future performance and include the Company's platform technology, a proposed redesign of Treatment Activators and tests involving the Company's TherOZap™ technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. In addition to other risks, the Company's redesign of the Treatment Activator may prove to be unsuccessful and tests involving TherOZap™ may prove to be unsuccessful against the Zika or West Nile virus' and the Company may be unable to complete the redesign of the Treatment Activator and the TherOZap™ technology. Further, the Company may not receive the redesigned Treatment Activator or TherOZap™ technology on the schedule it expects to receive the redesigned Treatment Activator or complete the tests as described in this news release or attract capital for marketing to ramp up sales or establish recurring revenue in the future to generate cash flow for the Company. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For Further information please contact:

The Jenex Corporation

Rob Fia
CEO & Chairman